Thermo Fisher Scientific (NYSE:TMO) Price Target Raised to $810.00

Thermo Fisher Scientific (NYSE:TMO) had its price target upped by TD Cowen from $760.00 to $810.00 in a research report released on Thursday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

A number of other equities analysts have also recently issued reports on TMO. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Saturday, October 3rd. Stifel Nicolaus raised their target price on Thermo Fisher Scientific from $650.00 to $775.00 and gave the company a “buy” rating in a research note on Thursday. Weiss Ratings raised Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Evercore set a $570.00 price target on Thermo Fisher Scientific in a research note on Monday, July 6th. Finally, Scotiabank initiated coverage on Thermo Fisher Scientific in a report on Wednesday, September 9th. They issued an “outperform” rating on the stock. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $681.00.

Thermo Fisher Scientific Stock Down 0.4%

Thermo Fisher Scientific stock opened at $673.97 on Thursday. The company has a market capitalization of $249.20 billion, a PE ratio of 35.55, a PEG ratio of 2.80 and a beta of 0.87. Thermo Fisher Scientific has a 12-month low of $435.27 and a 12-month high of $705.78. The firm’s fifty day moving average is $645.72 and its 200 day moving average is $554.80. The company has a quick ratio of 1.18, a current ratio of 1.81 and a debt-to-equity ratio of 0.71.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The business had revenue of $12.14 billion during the quarter, compared to analysts’ expectations of $11.95 billion. During the same period last year, the company posted $5.79 earnings per share. The business’s quarterly revenue was up 9.1% on a year-over-year basis. As a group, sell-side analysts predict that Thermo Fisher Scientific will post 25.23 EPS for the current fiscal year.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, VP Lisa P. Britt sold 11,440 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $613.12, for a total value of $7,014,092.80. Following the completion of the sale, the vice president directly owned 14,784 shares of the company’s stock, valued at $9,064,366.08. This represents a 43.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO Joseph R. Holmes sold 420 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This represents a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 73,768 shares of company stock worth $44,122,820. 0.33% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of TMO. BlackRock Inc. bought a new position in Thermo Fisher Scientific during the 2nd quarter valued at $15,501,867,000. Bank of New York Mellon Corp bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $1,974,561,000. Bank of America Corp DE bought a new stake in shares of Thermo Fisher Scientific in the 2nd quarter worth $1,952,930,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Thermo Fisher Scientific by 0.9% in the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock valued at $1,239,625,000 after purchasing an additional 22,827 shares during the last quarter. Finally, Legal & General Group Plc purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at about $1,122,351,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q3 earnings and revenue beat expectations. Thermo Fisher reported adjusted earnings of $6.68 per share versus the $6.40 consensus, while revenue rose 9.1% year over year to $12.14 billion, topping estimates of $11.95 billion. TMO Q3 deep dive: pharma demand, AI integration, and end-market recovery drive momentum
• Positive Sentiment: Analysts raised their valuation targets. TD Cowen increased its target to $810 and maintained a buy rating, while Stifel raised its target to $775 and Baird lifted its target to $756 with an outperform rating. These revisions imply meaningful upside from recent trading levels. TD Cowen analyst ratings
• Positive Sentiment: Improving end markets support the growth outlook. Investor commentary highlighted a broad-based recovery across life-science markets, including pharmaceutical demand, AI-related applications and other research tools. Erste Group also modestly raised its FY2027 EPS estimate to $27.58 from $27.51. Thermo Fisher benefits on broad-based recovery
• Neutral Sentiment: Secular market growth provides a longer-term tailwind. Industry forecasts call for strong expansion in next-generation sequencing kits and peptide synthesis, markets in which Thermo Fisher participates, although these reports do not directly change near-term earnings. NGS kits market forecast
• Negative Sentiment: Options activity signals caution. Heavy put-option buying indicates that some traders are hedging against, or positioning for, a pullback. The muted reaction to the earnings beat may also reflect elevated expectations and a relatively rich valuation. Thermo Fisher stock sees heavy put option buying

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.